Recently, a retrospective study conducted a double staining of PD-L1 and PAX5 in DLBCL samples in order to precisely quantify the rate of PD-L1+ cells in both the tumor and non-tumor compartments [54]. The gene discussed is CD274; the disease is neoplasm.